Table 1.

Clinicopathological characteristics of all patients with NSCLC and associations between CD47 expression and macrophage immune features

Characteristic	Total	CD47pos†	CD47neg†	M1 infiltration		M2 infiltration		M2/M1
				T&NT	NT	T&NT	NT	≥1	<1
	(n=191)	(n=63)	(n=128)	(n=57)	(130)	(n=89)	(n=98)	(n=134)	(n=53)
Age (years)
<65	111	35	76	32	78	54	56	81	29
≥65	80	28	52	25	52	35	42	53	24
P value		0.615		0.622		0.624		0.473
Gender
Female	69	30	39	20	46	26	40	42	24
Male	122	33	89	37	84	63	58	92	29
P value		0.020*		0.969		0.097		0.072
Smoking history
Never-smoker	89	41	48	27	60	39	48	61	26
Smoker	102	22	80	30	70	50	50	73	27
P value		<0.001**		0.878		0.480		0.662
Histology
LUAD	98	51	47	34	61	41	54	63	32
LUSC	93	12	81	23	69	48	44	71	21
P value		<0.001**		0.256		0.217		0.100
Tumour stage
I	96	28	68	27	66	28	65	55	38
III	95	35	60	30	64	61	33	79	15
P value		0.259		0.669		<0.001**		<0.001**

Data are listed as n.

*p value<0.05, ** p value<0.001.

†Cases with CD 47 IHC scores of 2+ or 3+ were considered positive for tumour CD47 (CD47^pos) expression. Cases with CD 47 IHC scores of 0 or 1+ were considered negative for tumour CD47 (CD47^neg) expression.

CD47^neg, CD47 negative; CD47^pos, CD47 positive; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; NSCLC, non-small cell lung cancer; NT, non-tumour area; T&NT, tumour area and non-tumour area.